A study reveals that different bacterial populations in regions of the lungs of cystic fibrosis patients descend from the same bacterial strain, suggesting diverse bacteria exist in each region.
The Research Development Program of the Cystic Fibrosis Foundation has expanded its network and awarded grants to various research sites in the US.
A recent study found that P. aeruginosa status in cystic fibrosis patients can have an impact on their lung microbiota composition.
There are several therapeutic techniques for airway clearance. But with all the options, how does an RT decide which is the most effective for the patient?
A potential link may exist between metabolic fingerprints and the progression of cystic fibrosis, according to a new study.
PARI Respiratory Equipment, Inc, has announced that its proprietary Kitabis Pak has been added to the Preferred Drug List (PDL) in more states across the United States.
The movement of patients within cystic fibrosis centers appeared likely to be an important risk factor for the acquisition of shared P. aeruginosa strain infections.
New research shows that microbes contributing to cystic fibrosis are able to survive in saliva and mucus that is chemically heterogeneous.
New research from the University of Pennsylvania revealed insight into the role of thiocyanate in the development of cystic fibrosis and other inflammation linked disorders.
The FDA has approved Vertex Pharma's Orkambi, the first drug directed at treating cystic fibrosis patients 12 years and older with two copies of the F508del mutation.
Monthly administration of liposome-delivered gene therapy for cystic fibrosis (CF) improved forced expiratory volume (FEV), according to a study published in Lancet Respiratory Medicine.
Spyryx is developing inhaled peptides designed to potently degrade ENaC (epithelial sodium channels), which play a role in mucus dehydration and reduced airway clearance.
In California, Hispanic patients with cystic fibrosis were three times as likely to die from the disease as their non-Hispanic counterparts, despite similar access to specialty care.
According to new research, the 5-year survival rate for Canadians with cystic fibrosis who have received a lung transplant is 67% and half of those who have had transplants live beyond 10 years.
Parion Sciences will receive $80 million in funding from Vertex Pharmaceuticals in a collaboration to develop a novel CF medication.
The development award will help support a Phase 2 clinical trial of the Celtaxsys's lead development candidate, a once daily, oral anti-inflammatory drug CTX-4430 in adults with cystic fibrosis.
A combination of the drugs Kalydeco (ivacaftor) and lumacaftor successfully treated the defective CF protein, improved lung function, and helped reduce pulmonary exacerbations by 40%.
Spyryx Biosciences, Inc, has raised $18 million in financing, which will be used to develop therapies to treat respiratory conditions including cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD).
Vertex's investigational drug Orkambi (lumacaftor/ivacaftor) could potentially treat 8,500 Americans with cystic fibrosis aged 12 and older with two copies of the F508del mutation.
The Food and Drug Administration (FDA) is questioning whether an experimental combination therapy for cystic fibrosis (CF) from Vertex Pharmaceuticals has any added benefits over Kalydeco.